Armata Pharmaceuticals (ARMP) Accumulated Expenses (2016 - 2026)
Quarterly results put Accumulated Expenses at $2.8 million for Q1 2026, up 108.98% from a year ago — trailing twelve months through Mar 2026 was $2.8 million (up 108.98% YoY), and the annual figure for FY2025 was $2.2 million, down 3.9%.
Armata Pharmaceuticals has reported Accumulated Expenses over the past 13 years, most recently at $2.8 million for Q1 2026.
- Accumulated Expenses reached $2.8 million in Q1 2026 per ARMP's latest filing, up from $2.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $2.8 million in Q1 2026 and bottomed at $768000.0 in Q4 2023.
- Median Accumulated Expenses over the past 5 years was $1.6 million (2025), compared with a mean of $1.6 million.
- The largest annual shift saw Accumulated Expenses crashed 57.99% in 2023 before it soared 196.88% in 2024.
- Over 5 years, Accumulated Expenses stood at $1.8 million in 2022, then plummeted by 57.99% to $768000.0 in 2023, then skyrocketed by 196.88% to $2.3 million in 2024, then fell by 3.9% to $2.2 million in 2025, then grew by 28.48% to $2.8 million in 2026.
- Business Quant data shows Accumulated Expenses for ARMP at $2.8 million in Q1 2026, $2.2 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.82 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 948,000.00 |
| Dec 31, 2023 | 768,000.00 |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 923,000.00 |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 1.71 Mn |
| Jun 30, 2021 | 1.22 Mn |
| Mar 31, 2021 | 893,000.00 |
| Dec 31, 2020 | 563,000.00 |
| Sep 30, 2020 | 1.30 Mn |
| Jun 30, 2020 | 966,000.00 |
| Mar 31, 2020 | 1.21 Mn |
| Dec 31, 2019 | 1.32 Mn |
| Sep 30, 2019 | 1.57 Mn |
| Jun 30, 2019 | 1.83 Mn |
| Mar 31, 2019 | 1.83 Mn |
| Dec 31, 2018 | 191,000.00 |
| Sep 30, 2018 | 1.75 Mn |
| Jun 30, 2018 | 1.37 Mn |
| Mar 31, 2018 | 965,000.00 |
| Dec 31, 2017 | 1.05 Mn |
| Sep 30, 2017 | 1.15 Mn |
| Jun 30, 2017 | 1.07 Mn |
| Mar 31, 2017 | 884,000.00 |
| Dec 31, 2016 | 895,000.00 |
| Sep 30, 2016 | 10,000.00 |
| Jun 30, 2016 | 72,000.00 |